Pasithea Therapeutics Corp./$KTTA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
- Ticker
- $KTTA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 5
- Headquarters
- Miami Beach, United States
- Website
- www.pasithea.com
KTTA Metrics
BasicAdvanced
$12M
-
-$1.11
0.29
-
Price and volume
Market cap
$12M
Beta
0.29
52-week high
$2.06
52-week low
$0.28
Average daily volume
253K
Financial strength
Current ratio
26.249
Quick ratio
24.845
Profitability
EBITDA (TTM)
-19.138
Management effectiveness
Return on assets (TTM)
-36.00%
Return on equity (TTM)
-65.49%
Valuation
Price to book
0.25
Price to tangible book (TTM)
0.27
Price to free cash flow (TTM)
-0.397
Free cash flow yield (TTM)
-251.88%
Free cash flow per share (TTM)
-0.927
Growth
Earnings per share change (TTM)
-79.03%
3-year earnings per share growth (CAGR)
-55.68%
What the Analysts think about KTTA
Analyst ratings (Buy, Hold, Sell) for Pasithea Therapeutics Corp. stock.
Analyst projections of the future price of Pasithea Therapeutics Corp. stock.
KTTA Financial Performance
Revenues and expenses
KTTA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.